



# Model List of Essential Medicines

## Caffeine citrate

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL) Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)	Apnoea of newborn

## Carbetocin

Section	Indications
Uterotonics Parenteral > General injections > IV: 100 µg per mL (heat stable)	Postpartum haemorrhage

## Chlorhexidine

Section	Indications
Medicines administered to the neonate [c] Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine) Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)	Omphalitis of newborn

## Clomifene

Section	Indications
Ovulation inducers Oral > Solid: 50 mg (citrate)	Female infertility without specification whether primary or secondary

## Condoms

Section	Indications
Barrier methods -	Contact with health services for contraceptive management

## Copper-containing intrauterine device

Section	Indications
Intrauterine devices -	Contact with health services for insertion of contraceptive device

## Dexamethasone

Section	Indications
Other medicines administered to the mother Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))	Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

## Diaphragms

Section	Indications
Barrier methods -	Contact with health services for contraceptive management

## Ergometrine

Section	Indications
Uterotonics Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)	Postpartum haemorrhage

## Estradiol cypionate + medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives Parenteral > General injections > IM: 5 mg + 25 mg	Contact with health services for reasons associated with reproduction

## Ethinylestradiol + etonogestrel

Section	Indications
Intravaginal contraceptives Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg	Contact with health services for contraceptive management

## Ethinylestradiol + levonorgestrel

Section	Indications
Oral hormonal contraceptives Oral > Solid: 50 µg + 250 µg [4]	Contact with health services for postcoital contraception
Oral > Solid: 30 µg + 150 µg	Contact with health services for contraceptive management

## Ethinylestradiol + norethisterone

Section	Indications
Oral hormonal contraceptives Oral > Solid: 35 µg + 1 mg	Contact with health services for contraceptive management

## Etonogestrel-releasing implant

Section	Indications
Implantable contraceptives Implant > Subdermal: 68 mg single rod	Contact with health services for insertion of contraceptive device

## Ibuprofen

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 5 mg per mL	Patent arterial duct

## Indometacin

Section	Indications
Medicines administered to the neonate [c]	Therapeutic equivalent to ibuprofen for Patent arterial duct

## Letrozole

Section	Indications
Ovulation inducers Oral > Solid > dosage form: 2.5 mg	Female infertility without specification whether primary or secondary

## Levonorgestrel

Section	Indications
Oral hormonal contraceptives Oral > Solid: 750 µg [2]; 1.5 mg [1]	Contact with health services for postcoital contraception
Oral > Solid: 30 µg	Contact with health services for contraceptive management
Intrauterine devices Intrauterine system with reservoir containing 52 mg of levonorgestrel.	Contact with health services for insertion of contraceptive device

## Levonorgestrel-releasing implant

Section	Indications
Implantable contraceptives Implant > Subdermal: 75 mg per rod (two-rods)	Contact with health services for insertion of contraceptive device

## Medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives Parenteral > General injections > IM: 150 mg per mL in 1 mL vial Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system	Contact with health services for reasons associated with reproduction

## Methylergometrine

Section	Indications
Uterotonics	Therapeutic equivalent to ergometrine for Postpartum haemorrhage

## Mifepristone - misoprostol

Section	Indications
Uterotonics Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package	Induced abortion Unspecified time of fetal death, cause not specified

## Misoprostol

Section	Indications
Uterotonics Oral > Solid: 200 µg Local > Vaginal > tablet: 25 µg	Spontaneous abortion, incomplete, without complication Unspecified obstetric condition Postpartum haemorrhage

## Multiple micronutrient supplement

Section	Indications
<p>Other medicines administered to the mother</p> <p>Tablet containing:</p> <p>Vit A: 800 mcg retinol activity equivalent</p> <p>Vit C: 70 mg</p> <p>Vit D: 5 mcg (200 IU)</p> <p>Vit E: 10 mg alpha tocopherol equivalent</p> <p>Vit B1: 1.4 mg</p> <p>Vit B2: 1.4 mg</p> <p>Vit B3: 18 mg niacin equivalent</p> <p>Vit B6: 1.9 mg</p> <p>Folic acid: 400 mcg</p> <p>Vit B12: 2.6 mcg</p> <p>Iron: 30 mg</p> <p>Iodine: 150 mcg</p> <p>Zinc: 15 mg</p> <p>Selenium: 65 mcg</p> <p>Copper: 2 mg</p>	<p>Maternal care for other specified conditions predominantly related to pregnancy</p>

## Nifedipine

Section	Indications
<p>Antioxytocics (tocolytics)</p> <p>Oral &gt; Solid: 10 mg (immediate-release)</p>	<p>Preterm labour without delivery</p>

## Norethisterone

Section	Indications
<p>Oral hormonal contraceptives</p> <p>Oral &gt; Solid: 350 µg</p>	<p>Contact with health services for contraceptive management</p>

## Norethisterone enantate

Section	Indications
<p>Injectable hormonal contraceptives</p> <p>Parenteral &gt; General injections &gt; IM: 200 mg per mL in 1 mL ampoule oily solution</p>	<p>Contact with health services for reasons associated with reproduction</p>

## Oxytocin

Section	Indications
Uterotonics Parenteral > General injections > unspecified: 10 IU per mL	Postpartum haemorrhage

## Progesterone vaginal ring

Section	Indications
Intravaginal contraceptives Local > Vaginal > vaginal ring: 2.074 g micronized progesterone	Contact with health services for contraceptive management

## Prostaglandin E1

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 0.5 mg per mL in alcohol	Other specified congenital anomaly of great arteries including arterial duct

## Prostaglandin E2

Section	Indications
Medicines administered to the neonate [c] Parenteral > General injections > IV: 1 mg per mL	Therapeutic equivalent to prostaglandin E1 for Other specified congenital anomaly of great arteries including arterial duct Other specified congenital anomaly of great arteries including arterial duct

## Surfactant

Section	Indications
Medicines administered to the neonate [c] Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation	Respiratory distress syndrome of newborn

## Tranexamic acid

Section	Indications
Other medicines administered to the mother Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Postpartum haemorrhage

## Ulipristal

Section	Indications
Oral hormonal contraceptives Oral > Solid: 30 mg tablet (ulipristal acetate)	Contact with health services for postcoital contraception